Zoetis Inc.

Zoetis Inc. が 2026年8月6日 に発表した内容

2026年6月30日 に終了した四半期、前年同期との比較。

これは単独四半期の数字であって通年ではありません——このサイトの他の場所の数字は 12 か月を対象としており、はるかに大きくなります。季節性のある事業は両者の間で大きく振れます：ServiceNow は 12 月期に 20 億ドルのフリーキャッシュフローを稼ぎ、6 月期には 5 億ドルです。

比較対象はアナリスト予想ではなく前年同期です。「上振れ」「下振れ」と言うにはコンセンサス予想が必要ですが、それは当方が保有しないライセンスデータであり——間違えるくらいなら載せないほうがましです。

経営陣の発言

“Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories,”

発表資料から逐語で引用し、書類が氏名のある人物に帰属させている場合にのみ表示します。

株価の反応

発表は引け後か寄り前に出るため、ここでの値動きは次の取引日のものです。

Zoetis Inc. の事業内容

Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven 4 | R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com. 1 Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures. 2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. 3 A blockbuster has annual sales of at least $100 million. DISCLOSURE NOTICES

発表資料の末尾に記載された、企業自身による説明です。